HDAC-IN-30;
HDAC-IN-30 是一种新颖的多靶点 HDAC 抑制剂,靶点主要有 HDAC1 (IC50=13.4 nM),HDAC2 (IC50=28.0 nM), HDAC3 (IC50=9.18 nM),HDAC6 (IC50=42.7 nM),HDAC8 (IC50=131 nM)。HDAC-IN-30 表现出非常强大的抗肿瘤作用。
HDAC-IN-30 Chemical Structure
CAS No. : 2756809-34-2
规格 | 是否有货 | ||
---|---|---|---|
100 mg | ; | 询价 | ; |
250 mg | ; | 询价 | ; |
500 mg | ; | 询价 | ; |
* Please select Quantity before adding items.
生物活性 |
HDAC-IN-30 is a novel multi-target HDAC inhibitor, including HDAC1 (IC50=13.4 nM),HDAC2 (IC50=28.0 nM), HDAC3 (IC50=9.18 nM), HDAC6 (IC50=42.7 nM), HDAC8 (IC50=131 nM). HDAC-IN-30 exhibits potent antitumor efficacy[1]. |
||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 Target |
|
||||||||||||||||||||||||
体外研究 (In Vitro) |
HDAC-IN-30 (compound 8 h; 0.5, 1, 2 μM; 48 hours) can effectively activate the p53 pathway by promoting the phosphorylation of p53[1]. HDAC-IN-30 (0, 1, 2.5, 5 mM; 48 hours; HepG2 cells) induces cell cycle arrest at the G2 phase in a concentration-dependent manner[1]. HDAC-IN-30 (0, 1, 2.5, 5 mM; 48 hours) possesses prominent anticancer activity in HepG2 cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis[1]
Cell Cycle Analysis[1]
Apoptosis Analysis[1]
|
||||||||||||||||||||||||
体内研究 (In Vivo) |
HDAC-IN-30 (12, 24 mg/kg; intraperitoneal injection, every two days for 4 weeks) exhibits potent anticancer activity and no side effects even at high dose (24 mg/kg)[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||||||||||
分子量 |
405.45 |
||||||||||||||||||||||||
Formula |
C22H23N5O3 |
||||||||||||||||||||||||
CAS 号 |
2756809-34-2 |
||||||||||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||||||||||
储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis. |
||||||||||||||||||||||||
参考文献 |
|